Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kylo-11 SAD Study in Healthy Subjects
NCT06363851Phase 1Completed
- Sponsor
- Kylonova Biopharma
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cardiovascular disease (CVD) comparing Kylo-11 with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 24 weeks. Started May 2024; status: completed.
02
Drugs
KYLO-11
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT06363851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363851.